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Pancreatic cancer is one of the most lethal cancers worldwide due to its symptoms,
early metastasis, and chemoresistance. Thus, themechanisms contributing to pancreatic
cancer progression require further exploration. Circadian rhythms are the daily oscillations
of multiple biological processes regulated by an endogenous clock. Several evidences
suggest that the circadian clock may play an important role in the cell cycle, cell
proliferation and apoptosis. In addition, timing of chemotherapy or radiation treatment
can influence the efficacy and toxicity treatment. Here, we revisit the studies on circadian
clock as an emerging target for therapy in pancreatic cancer. We highlight those potential
circadian genes regulators that are commonly affected in pancreatic cancer according
to most recent reports.
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INTRODUCTION
Pancreatic cancer is the 15th most common malignancy and ranks 7th among malignant cancers
in terms of death (1). On top of that, this cancer represents one of the most malignant types of
tumors, being the fourth leading cause of cancer-related death in the United States and the sixth in
China (1). Unfortunately, without any substantive improvement in the current curative therapies,
the pancreatic ductal adenocarcinoma could possibly be the second leading cause of cancer-related
death by 2030 (2).
The mammalian circadian system consists of a central clock in the hypothalamic
suprachiasmatic nucleus (SCN), and peripheral clocks in other brain regions and tissues
throughout the body, including muscle, adipose tissue, liver, colon and pancreas. The SCN receives
information about the 24 h light:dark cycle trough the retina and this timing signal is forwarded via
neural and hormonal signals and body temperature to the peripheral clocks in order to maintain
organism homeostasis (3, 4). This circadian clock is essential for the endocrine system, as it
requires the accurate timing communication among the different organs that composed it to ensure
the correct response and anticipation to the environmental changes or stresses (5). Disruption
on circadian clock has been also linked to initiation, progression, metastasis, and resistance to
treatments in cancer (6–11). Thus, analysis of circadian function could lead could lead to the
identification of prognostic markers and therapeutic targets for specific cancers (12).
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Specifically, the pancreas is one of the organs most influenced
by this timing system, since it possesses its own clock regulated
by the SCN and non-photic signals to keep its normal physiology;
but also because it is closely linked to its endocrine function (13).
All this knowledge has led to the development of clinical trials to
improve its function trough time management of treatments (14,
15). In vitro and in vivo studies demonstrated that circadian clock
disruption is also linked to the development and progression as
well as treatments resistance in pancreatic cancer. In this review,
we highlight most recent results in such aspects of this type
of cancer that could help the identification of prognostic and
predictive factors and the development of personalized medicine
for patients suffering from this disease.
THE MOLECULAR CIRCADIAN CLOCK
The rotation of the Earth around its own axis each 24 h generates
a constant daily sunlight-darkness cycle, which conditions the
behavior and the activity of organisms. In order to adapt and
anticipate to the environmental cues resulting from these 24-h
rhythmic oscillations, organisms have developed an endogenous
timing-keeping mechanism known as circadian clock. However,
this circadian clock regulates rhythmicity far beyond sleep-wake
cycles. Circadian clock governs physiological and biochemical
rhythms of processes related to hormone secretion, blood
pressure, cell division, body temperature, immune function and
metabolism, since they fluctuate over an ∼24-h period (16).
These rhythms have three characteristic hallmarks: they drive
rhythms with a period of about 24-h, which are endogenous
and persist in constant conditions; they remain synchronized
with their environment, being resettable by external changes;
and they should be temperature compensated, i.e., their periods
are not affected by temperature (17). Disruption in functional
circadian rhythm results in different physiological disorders
such as cardiovascular diseases (18), metabolic syndrome
(16), neurodegenerative disease (19), endocrine disruption and
cancer (20).
In mammals, the circadian system is organized in a
hierarchical system composed by a network of multi-oscillator
circadian clocks. This network integrates a master pacemaker or
central clock, which is located in the hypothalamic SCN, and
a series of peripheral clocks present in virtually all tissues and
cells. The SCN is able to receive information of the external
light through the retina to couple the daily physiological rhythms
to the environmental cues. This information is transmitted via
neural and humoral pathways to the peripheral clocks in order to
synchronize them and to provide proper rhythms in these tissues
(21). However, light is not the only signal that allows peripheral
clocks to entrain the rhythms, since they could response to non-
photonic signals such as food (22) or drugs (23). Peripheral
clocks can also generate circadian rhythms independently, being
observed in cultured cells (24), or even in stem cells upon
differentiation during development (25, 26).
At molecular level, circadian rhythms are controlled by a
cell-autonomous genetic network of transcription/translational
feedback loops (TTFL) of circadian clock genes that regulate
themselves. The core loop is driven by the expression of
BMAL1 (Brain and Muscle ARNT-Like 1) and CLOCK
(Circadian Locomotor Output Cycles Kaput), which are
expressed during the day, interacting with each other to
produce CLOCK:BMAL1 heterodimers in the cytoplasm. These
heterodimers are translocated to the nucleus, where they act
as transcription factors of elements containing E-boxes. Their
targets include the transcriptional repressors period (PER1-3)
and cryptochrome (CRY1-2) genes. PER and CRY proteins can
also form a heterodimer in the cytosol. Once translocated to
the nucleus, PER:CRY heterodimers binds to CLOCK:BMAL1,
inhibiting their own transcription and decreasing PER and
CRY protein levels. This allows a new cycle of transcription by
CLOCK:BMAL1, closing the cycle. Additionally, BMAL1 levels
are also tuned by a stabilizing loop controlled by RORα and
REV-ERα-β , whose expression is controlled by CLOCK:BMAL1
as their promoters contain E-boxes. REV-ERα-β and RORα
shared DNA binding motifs, competing between them to
inhibit or promote, respectively, BMAL1 expression (27, 28).
CLOCK:BMAL1 also drives a transcriptional loop in which
the factors DBP (D-box binding protein), TEF (thyrotroph
embryonic factor), and HLF (hepatic leukemia factor) interacts
at sites containing D-boxes with the repressor NFIL3 (Nuclear
Factor, Interleukin 3 Regulated; or E4BP4), which is driven
by the REV-ERB/ROR loop (29, 30). Proteins of the core
circadian clock drive rhythmic expression of the called clock-
controlled genes (CCGs). These CCGs are tissue-specific, and
ultimately are responsible for the physiological requirements
and characteristics of every organ, accounting for 43% of all
protein-coding genes in at least one organ (31).
The molecular regulation of the circadian clock is far
beyond of just TTFLs. Recently, it has been described an
epigenetic control of circadian transcription, at the level of
DNA methylation as well as in the modifications of histones.
Additionally, tissue-specific transcription factors, nuclear
receptors, or some regulators of intracellular signaling can
determine a portion of the circadian transcriptome in response
to environmental cues (32, 33).
In addition, a machinery of post-translational modifications
is involved in the regulation of the correct ticking of the
clock, adding a new layer of complexity (34). Phosphorylation
is one of the key post-translational modifications, which is
involved in regulating the core clock loop, as well as the
downstream CCGs (35). The stability/degradation rate of the
PER and CRY proteins is mediated by different pathways and
is a key issue to maintaining the rhythm period. CK1ε/δ-
mediated phosphorylation of PER proteins is necessary for
their ubiquitination by βTrCP and degradation by the 26S
proteasome. CRY1 and CRY2 are phosphorylated by AMPK and
DYRK1A/GSK-3β, respectively, and then polyubiquitinated by
FBXL3 (35). Acetylation/deacetylation is another mechanism of
post-translational modifications of clock proteins. Although the
enzyme(s) responsible for PER2 acetylation remain(s) unknown,
Asher et al. reported that SIRT1, a class III histone deacetylase,
is bound to the CLOCK:BMAL1 complex in a circadian fashion
and promotes the deacetylation and subsequent degradation
of PER2 (36). Nakahata et al. observed that SIRT1 is bound
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to the CLOCK:BMAL1 complex at the circadian promoters
and deacetylates BMAL1 at Lys537 (37). Furthermore, the
inhibition of SIRT1 activity leads to significant disturbances in
the circadian cycle and to the acetylation of histone 3 (H3)
and BMAL1 (36). Interestingly, the HDAC activity of SIRT1
is regulated in a circadian manner both in vitro and in vivo
(36). Further post-translational modifications that participate
in tuning the molecular clock and clock-controlled proteins
comprise ubiquitination, SUMOylation, or methylation (38).
Embryonic stem cells express circadian clock proteins, but
they do not oscillate as they do not possess a functional TTFL (25,
26), however they show circadian rhythms for glucose utilization
and glucose transporter transcription. This reveals the existence
of circadian rhythms independent of the molecular clock (39).
The main evidence of transcriptional-independent circadian
rhythm comes from red blood cells (RBCs), since they are
anucleated cells, and therefore incapable of transcription. RBCs
show circadian peroxiredoxins (PRDX) oxidation/reduction
rhythms (40). PRDX are a family of conserved enzymes involved
in the regulation of peroxide levels. A subclass of PRDX, known
as 2-Cys PRDX, during the process of reducing peroxide is
oxidized to a sulfenic acid form (PRX-SO), which need to be
reduced by a thioredoxin to be active again. Nevertheless, a
fraction of PRX-SO is hyperoxidized to sulphinic and sulphonic
acid forms (PRX-SO2 and PRX-SO3), which gives rise to an
inactive form of the enzyme until they are recycled by a
sulfiredoxin through an ATP-dependent reduction (41, 42). The
levels of these forms oscillate through a 24-h pattern and met
the 3 hallmarks of circadian rhythms previously indicated. RBCs
also show circadian oscillations in others redox processes such as
hemoglobin tetramer-dimer transition and NAD(P)+/NAD(P)H
oscillations (40). The TTFLs and redox/metabolic cycles are
interconnected and individually necessary for the maintenance
of rhythms at the cellular level (43–46). The existence of
non-transcriptional clock mechanisms along with the evidences
of interplay between cellular redox/metabolic oscillations and
circadian clocks (47) suggested a new layer in the circadian
system. While regulation of metabolic output by the circadian
clock is well-established, the mechanism by which metabolite
fluctuations can also contribute to circadian clock adjustments
is less know (48–50). Very recently, Levine et al. demonstrated
in aged mice a role for NAD+ in remodeling the circadian
transcriptome through SIRT1-mediated deacetylation of the core
clock repressor PER2, which in turn promotes the activity of
CLOCK/BMAL1 (51). Other studies revealed rapamycin (TOR)
kinase, a conserved central growth regulator, as essential for
the metabolic control of the circadian period in plants (52). In
mammals, the tight junction protein 1 (TJP1) functions as a
mediator of mTOR to modulate the hepatic circadian clock (53).
Thus, perturbations in the circadian clocks are a hallmark of
human metabolic diseases (54).
CIRCADIAN RHYTHMS AND CANCER
The closely interplay between the circadian system and cancer
has been shown through epidemiological studies, in which
associations between shift work and higher risk for developing
cancer has been found (8, 10, 55). Human rotating working
schedules (as cause for circadian disruption) are, in fact,
considered by the WHO as a IARC 2A carcinogen (56);
but it is not the only situation related to schedule that can
contribute to cancer. For instance, a Spanish study found a
relationship between having dinner before 9 p.m., and long
interval between last meal and sleep, with a lower risk for
breast and prostate cancer (9). Additionally, loss of circadian
homeostasis is associated with poor prognosis, worse response to
treatment and higher mortality in different cancers (6, 7).
These evidences have been corroborated in animal model
studies, in which genetic and environmental controlled circadian
disruption promotes cancer development. Filipski et al. showed
howGlasgow Sarcoma progression was accelerated inmice under
chronic jet lag conditions (an advance of light onset by 8 h every
2 days) rather those exposed to control conditions (alternation of
12 h of light and 12 h of darkness, normal circadian rhythmicity)
(57). A similar effect was seen by Papagiannakopoulos et al.,
who saw decreased survival and promoted lung tumor growth
and progression in mice exposed to prolonged jet lag conditions
(58). In the same study, the authors genetically manipulated the
circadian genes Per2 (Per2m/m) and Bmal1 (Bmal1−/−) in whole-
animal bodies, exhibiting the same previous effects describes, and
so, pointing out their tumor-suppressive role in lung cancer (58).
The contribution of a gene to cancer development is
established in base of its observed mutation rate. Although clock
genes mutations occur at low rate, they are related with prognosis
and overall survival in cancer. In addition, their expression seems
to be altered in several cancers (59). Ye et al., systematically
analyzed the genetic and clinical data of The Cancer Genome
Atlas (TCGA) in relation to clock genes (core and related clock
genes) for 14 cancer types, showing that 90.2% of these genes
were differentially expressed in at least one cancer type (59).
BMAL2 and REV-ERα were upregulated in 9 and 8 cancer types,
respectively, suggesting they may act as oncogenes. Meanwhile,
others clock genes were downregulated including PER1 in 11
cancer types, PER2 in 7, PER3 and CRY2 in 10 and RORα in
11, indicating they may act as tumor suppressor genes (59).
However, some of them despite of the overall downregulated
expression were found upregulated in few cancer types. In this
context, CRY2 and PER3 showed overall downregulation but
were upregulated in kidney chromophobe and in kidney renal
clear cell carcinoma (KIRC), respectively; or NR1D1, which
was upregulated in general, was downregulated in BRCA triple-
negative breast cancer (59). These data suggest that clock genes
may play different roles in different tumor environments and
tissues. Clock genes are highly associated with activation or
inhibition of oncogenic pathways, with CRY2 playing a dominant
role in cancer development (59).
Circadian genes, along with the circadian rhythm itself, may
participate in the development of cancer hallmarks: deregulation
of cell cycle, apoptosis, DNA damage response and metabolism.
The cell cycle depends on the building up complex of specific
cyclin-dependent kinases (CDKs) and cyclins at specific times in
a very tight process in order to restrict uncontrolled proliferation.
Despite of the similarities about the oscillatory behavior between
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the cell cycle and circadian clock, its relationship is still not fully
understood. Clock proteins control the circadian expression of
several cell cycle components such as Wee1, c-Myc, p20, p21,
and p53 among others (60). WEE1 protein transcription, an
inhibitor of G2-M transition, is activated by BMAL1:CLOCK,
but, inhibited by PER and CRY allowing the cell cycle to
continue (61). C-MYC plays a pivotal role in cancer taking
part in multiple processes, such as metabolism, cell cycle and
apoptosis, and its deregulation along with the loss of p53
is associated with the maintenance of the cancer stem cells
(CSC) pool as well as the promotion of genomic instability
and the inhibition of apoptosis even after severe damage (62,
63). C-myc gene is directly suppressed by CLOCK:BMAL1
since its promoter possess E-boxes (64), and is stabilized by
PER1, suppressing p21 expression, allowing the cell cycle to
continue (65). P21, is also inhibited or activated by REV-
ERBα and RORα, respectively (66). At protein level, c-MYC
turnover is regulated by CRY2. In this process, CRY2 cooperates
with the E3 substrate receptor FBXL3 to degrade c-MYC in a
phospho-specific manner contributing to circadian protection
from tumorigenesis (67). P53 is a transcription factor involved
in several biological processes, whose products exert a tight
control of many cell cycle checkpoints. P53 stability and
transcriptional activity is modulated by PER2 in unstressed cells
by blocking Mdm2-dependent ubiquitination and transcription
of p53 target genes (68). Per2 forms a trimeric complex with
p53 and Mdm2 (68) and dimeric complexes with p53 alone
with differential spatial distribution that also influences p53’s
downstream response under genotoxic stress (69). However, the
phase relationship between PER2 and p53 are opposite, revealing
a node of regulation where circadian and checkpoint components
can bi-directionally communicate and influence each other’s
downstream signaling (70). In fact, PER2 interact with MDM2,
and MDM2 target of PER2 for degradation (71). In addition,
p53 also regulates PER levels by binding to its promoter and
repressing it, resulting in a disruption of the positive loop and
shifting of circadian cycle (72).
Another link between the circadian clock and the cell cycle
is exerted through the response to DNA damage mediated by
ATM and ATR. In humans, the circadian protein Timeless (TIM)
exerts the link among cell cycle, DNA damage response and
circadian rhythm. Human TIM was found to form a complex
with CRY2, checkpoint kinase 1 (CHK1) and ATR to regulate S
phase and DNA damage response (73). This is not the only cell
cycle checkpoint in which TIM is involved, as it also interacts
with CRY to regulate the ATR/CHK1-mediated G1/S transition
checkpoint, as well as the G2-M transition by interacting with
ATM/checkpoint kinase 2 (CHK2) and PER (65, 74).
Regarding cancer cells metabolism, tumor cells reprogram
their metabolism toward a high glycolysis rate followed to lactate
fermentation even at oxygen conditions (75). This increase
of glycolysis leads to an increment of reactive oxygen species
(ROS), and the subsequent DNA damage; accumulation of
intermediates rerouted to biosynthetic pathways for growing and
proliferation (75); and the acidification of themicroenvironment,
which in turn may disrupt the circadian clock at the niche
(76). The metabolism programme switch may be produced
by the activation of PI3K/AKT pathway, and by the hypoxia
response pathway mediated by HIF-1α, both related with
circadian rhythm (77, 78). Specifically, HIF-1α was found to be
a direct transcriptional target of NPAS2, which mediates both
the upregulation of glycolytic genes and the downregulation
of mitochondrial biogenesis in hepatocellular carcinoma (HCC)
(79). It should be noted that, in this case, overexpression
of a component of the circadian clock occurs, instead of
down-expression. On the contrary, lack of PER2 increases
PI3K/AKT/mTOR signaling pathway, protein synthesis and cell
proliferation and decreases autophagy in this type of cancer (80).
Other signaling pathways implicated in HCC development are
regulated trough circadian clock, such as WNT/β-Catenin, MAP
Kinase and Hedgehog signaling pathways. Other studies showed
that loss of hepatocyte nuclear factor 4 alpha (HNF4α) in the
liver combined with high fat feeding in mice induced EMT in an
IL6-dependent manner (81). The HNF4α gene encodes different
isoforms. P1-HNF4α, the predominant isoform expressed in the
adult liver, inhibits the expression of tumor promoting genes in
a circadian manner. In contrast, P2-HNF4α isoform represses
BMAL1, causes cytoplasmic re-localization of P1-HNF4α and
HCC grown (82). Therefore, a deeper understanding of circadian
clock is promising for developing new strategies for HCC
prevention and management (83), a disease in growing incidence
in both men and women, because it is linked to non-alcoholic
fatty liver disease (NAFLD) and to obesity (81).
Translated to the clinical practice, all these processes
controlled, to a greater or lesser extent, by the circadian clock
are interesting as possible targets for new approaches. To
the day, circadian rhythms are being used as a treatment in
two different ways: targeting the clock or CCG products and
chronotherapy. The first approach tries to target the circadian
components or restores normal circadian oscillations. A recent
study shows how SR9009 and SR9011, two agonists against
REV-ERBs, impair glioblastoma growth and survival without
affecting surrounding healthy cells in mice (84), although the
authors did not analyze whether these compounds affect central
or local (tumoral) circadian rhythmicity. Other authors have
seen how treatments with dexamethasone, forskolin and heat
shock to induce circadian rhythmicity slow down tumor growth
on B16 murine melanoma cells and human colon carcinoma
HCT116 (85).
On the other hand, chronotherapy, the administration of
a drug at optimal times based on the individual’s circadian
rhythm in order to maximize the therapeutic effects and
minimize the toxic ones, appears to be a new way to improve
the current treatments. Li et al. developed a MAP Bayesian
interference method to determine the optimal timing for
irinotecan administration based on rREV-ERBα and BMAL1
expression, achieving a decrease of toxicity (86). Another study
carried out by Dakup et al. points out the application of cisplatin,
a widely used chemotherapeutic agent but limited by its toxicity
and resistance, at the evening reduces toxicity compared to the
morning in wild type mice, but no time-of-the day difference was
observed in Per1/2−/− (87). Since it is known that most of the
drug targets, not only anti-cancer drugs, are components with
circadian behavior (31), the optimum circadian time for their
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application should be determined before trial phases, as well as,
it opens the door to reconsider drugs that were not successful in
II and III trial phases, and applied them in a circadian manner.
However, it is important to note that, its application to clinical
practice is still complicated since circadian rhythms are not fully
understood, due to the necessity for the optimization of drug
protocols to be as efficient as possible and tumor heterogeneity.
Tumor heterogeneity is associated, in part, to the presence
of CSCs (88). CSCs are a distinct proportion of the cancer
cells present in the tumor, characterized by their tumorigenesis,
differentiation and self-renewal capacities, but also by a slow cell
cycle and an increase of ABC transporters which allow them to
evade cancer therapies (89). Those characteristics have them led
to be considered as a key player in metastasis and relapse, and
may be the origin of a cancer process. The circadian properties of
CSCs remain unknown, likely to the difficulty to isolated, based
on the presence of stemness markers such as ALDH1, CD44, or
CD133 among others, and work with them in vitro and in vivo
(90). However, some interesting progresses has been made with
the role of circadian clock in leukemic stem cells (LSCs) (91) and
glioblastoma stem cells (GSCs) (92). Puram et al., using a murine
model of acute myeloid leukemia (AML) and in vitro human
cells lines, found that normal and malignant hematopoietic cells
harbor an intact robust clock, but the knockout of BMAL1 and
CLOCK resulted in an impairment of tumor cells, meanwhile
normal hematopoietic function was not affected. The knockout
also results in an increment of myeloid differentiation markers
and reduction of stem cell markers in leukemia cells, pointing
out the importance of the circadian role in the maintenance and
function of LSCs (91). On the other hand, Dong et al., showed
how BMAL1 and CLOCK act as oncogenes in glioblastoma.
These genes are necessary for GSCs proliferation and survival,
but they are not required for differentiated glioblastoma cells or
normal neural stem cells. In GSCs, the clock machinery seems
to regulate glucose metabolism and lipid synthesis, while this
control is not exerted in normal neural stem cells, being these
differences attributed to distinctive changes in chromatin (92).
Both cases show the relevance of circadian programming in
CSCs, and, although it is still poorly understood, they reflect
how is the reprogramming of the circadian regulation, rather
than the rhythm itself, what is needed to understand in CSCs
and cancer in order to use the circadian clock as target or tool
for therapies. Circadian dynamics of CSCs are regulated by the
tumor microenvironmental factors. The number of CSCs (high
ALDH activity cells) in a mouse breast tumor model exhibited
accused circadian alterations, which was a cause of the time-
dependent release of WNT10a from non-CSCs (ALDH-negative
cells) of tumors. With these results in mind, Matsunaga et al.,
demonstrated that the antitumor and antimetastatic effects of the
ALDH inhibitor N,N diethylaminobenzaldehyde (DEAB) were
improved by changing the dosing schedule of the drug (93).
As mentioned before, circadian rhythms are regulated in
part by epigenetics modifications; however the link between
circadian clock and epigenetic machinery is reciprocal (32,
33, 94). Circadian gene silencing has been implicated in
several aspects of cancer, directly as well as indirectly due to
regulation of cancer-related CCGs (94). On the other hand,
the circadian molecular system modulates the daily variation in
DNA methylation, with increased levels at night (95). In relation
to histone modification, core clock genes and clock output
genes underlay rhythmic histone modifications. Core circadian
genes are regulated by histone phosphorylation, acetylation and
methylation (94). Interestingly, CLOCK protein has histone
acetyltransferase (HAT) activity directed to BMAL1 and histone
H3 (96) and, acting with other HAT, to the promoters of CCGs
to enhance transcription (97). SIRT1 counteract the activity
of CLOCK and deacetylates BMAL1, as described previously
(36, 37). Other acetylases and histone deacetylases, participate
in the regulation of clock gene transcription. Alterations in
these epigenetic control mechanisms could be a key factor
during carcinogenesis (32). In addition, aberrant patterns of
histone methylation and phosphorylation have been reported in
cancer (33).
THE ROLE OF CLOCK GENES IN
EXOCRINE AND ENDOCRINE
PANCREATIC FUNCTION
Peripheral oscillators operating in metabolic organs, such as the
liver, muscle, white adipose tissue, pancreas and gut, function in
concert with the central clock to orchestrate glucose, lipid and
protein metabolism (54). The pancreas is an organ with a dual
role: endocrine and exocrine functions.
As exocrine gland, it secretes pancreatic juice with digestive
enzymes into the duodenum. In this case, circadian clock is
involved in two important aspects of pancreatic physiology.
Throughout embryonic development, the core circadian gene
Clock regulates timing of pancreatic differentiation in mouse
through the Wnt and Notch pathways as well as cell cycle
regulators. Disruption of Clock and Timeless in the embryonic
pancreas does not block pancreatic differentiation but alters
the balance and maturity of endocrine and exocrine cells (98).
Exocrine pancreas in adult rats exhibits a chrono-morphological
pattern in the shape coefficient of glandular acini (99).
Exocrine pancreatic secretion showed a circadian rhythm,
with secretory rates increasing in the dark period and decreasing
during the light period in rats (100). In pigs, a biphasic pattern
of the exocrine pancreas, postprandial peak and between meals
was detected (101). In humans, pancreatic exocrine secretion and
intestinal motility are coupled with different circadian rhythms.
Intestinal motility follows a circadian rhythm with reduced
motor activity during the night. In contrast, pancreatic amylase
output increases significantly during the night, whereas protease
output remains unchanged. The cyclical coupling between
interdigestive motility and pancreatic secretion is preserved
throughout the circadian cycle and seems to be not caused by
increased cholinergic activity (102). In the course of chronic
pancreatitis, the presence of severe exocrine insufficiency induce
longer periods of gastric acid exposure, indicating that gastric
acidity, exocrine pancreatic insufficiency, and impaired digestion
are closely related (103).
The endocrine function is exerted by the islets of Langerhans
composed of α-cells and β-cells. Those cells are responsible
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for controlling glycaemia by secreting glucagon (α-cells) and
insulin (β-cells) at hypoglycaemic or hyperglycemic conditions,
respectively, with opposite effects on glucose metabolism (104).
An impairment on insulin secretory function of β-cells as
well as the increasing of β-cell apoptosis are the principal
abnormalities which lead to insulin resistance in liver, muscle
and adipose tissue; and eventually to the development of type
2 diabetes mellitus (T2DM) (105). It is widely accepted that the
development of T2DM is caused by multiple factors combining
lifestyle (obesity and diet mainly) and genetics (106). However,
in the last few years, there is a growing evidence of the
association between alterations in the circadian rhythms and the
development of T2DM (107–109). In fact, some studies, in mice
and humans, highlight the necessity of a functional circadian
clock on the pancreatic isles cells for proper insulin secretion
(50, 110).
Under physiological conditions, humans present a strong
time-of-day effect in glucose tolerance, with a peak in the
morning/awakening, concurring with the maximal glucose
plasma concentrations and glucose uptake. This glucose
tolerance is decreased through the day, being minimal at night,
likely as an effect of insulin tolerance, showing a circadian
behavior (111).
Briefly, the production and release of insulin from β-cells
involve the production of insulin and granule formation; glucose
uptake by GLUT2 receptors; and glycolysis and ATP formation
by mitochondria, which initiates a cascade reaction mediated
by inhibition of ATP-sensitive potassium channels and opening
of voltage-dependent calcium channels. This increases Ca2+
intracellular levels which eventually results in glucose-stimulated
insulin granule secretion. Almost every of these processes
are impaired in T2DM, and are under the tight control of
the circadian genes, as demonstrated in BMAL1 and CLOCK
knockout studies in different in vitro and in vivo models (110,
112, 113).
Saini et al., using small-interfering RNA-mediated knockdown
of CLOCK (siClock) demonstrated the profound impact of
CLOCK disruption on insulin secretion (110). The disruption
of CLOCK gene does not affect Insulin (INS) expression but
it downregulates the expression of SLC30A8, VAMP3, and
STX6 which are involved in insulin granule formation, vesicle
trafficking, and secretion (110). SLC30A8 encodes for the Zinc-
Transporter SCL30A8 which is required for proper insulin
synthesis, storage and secretion (114), meanwhile VAMP3 and
STX6 proteins take part of a complex involve in granule fusion
with the plasma membrane (115). CLOCK disruption also
affects to the intracellular signal transduction cascade required
for glucose-stimulated granule secretion, as GNAQ (Guanine
nucleotide-binding protein, subunit α), ATP52G2 (ATP synthase,
mitochondrial F0 complex H+, subunit C2), and ATP1A2
(Na+/K+-transporting ATPase, subunit α-1) are downregulated,
and KCNJ11 (potassium channel, inwardly rectifying subfamily
J member 11) is upregulated, leading to decrease glucose-
stimulated ATP production and membrane hyperpolarization,
respectively, altering glucose-induced insulin secretion (110).
On the other hand, Bmal1 disruption reveals the importance
of Bmal1 in the prevention of oxidative stress in β-cells. Lee
et al. generated mice with β-cell deleted Bmal1 (β-Bmal1−/−),
showing an increase of ROS and mitochondrial uncoupling
(116). The absence of functional Bmal1 results in the decrease
of the antioxidant regulatory factor Nrf2, and so the absence
of its transcriptional target genes Sestrin2, Prdx3, Gclm, and
Gclc, which inhibits the antioxidant responses in β-Bmal1−/−
(116). Parallel to these events, or as a result of the ROS
accumulation increase, there is an upregulation of Ucp2 which
generates oxidative stress-induced uncoupling of mitochondria
and impairment of glucose-induced insulin secretion (116).
The loss of β-cells by apoptosis, another feature of T2DM,
can be linked to a non-functional circadian clock. Saini et al.,
reported a downregulation of genes that can reduce apoptotic cell
death (FURIN, PRDX3, PPP2CB, and BTG) and an upregulation
of genes that can induce apoptosis (PSEN2, SQSTM1, ACVR1B,
GCH1, HTT, and ARHGEF3) after clock disruption (110).
Also, the absence of Prdx3 and Gclc, two important agents in
preventing oxidative stress-induced apoptosis in β-cells, in β-
Bmal1−/− may trigger the death of pancreatic β-cells (116, 117).
Another circadian gene that play an important role in
endocrine pancreatic function is REV-ERBα whose lack of
expression is related to impaired insulin secretion and cell
proliferation reduction (118). Outside of the circadian genes,
there are other genes with circadian-manner expression with
have an important role on β-cells homeostasis such as
DBP (albumin site d-binding protein) and TEF (Thyrotroph
embryonic factor) transcription factor. TEF seems to control the
expression of GLUT2 under circadian behavior (119), meanwhile
DBP regulates the circadian expression of ARNT/HIF-1β , which
may have a role in connecting circadian rhythm and metabolism,
being impaired in T2DM (120). Taken together, the endocrine
pancreatic function is strongly associated with circadian rhythms.
Alteration of the rhythms leads to an impairment function of
β-cells and increasing risks for of T2DM development.
Non-alcoholic fatty pancreas disease (NAFPD) describes
a phenotype of pancreatic steatosis not caused by alcohol
consumption, viral infections, toxins, or congenital metabolic
syndromes, and ranging from deposition of fat in the pancreas
to pancreatic inflammation, and resultant fibrosis. Together with
T2DM, cardiovascular and cerebrovascular diseases and non-
alcoholic fatty liver disease (NAFLD) is considered a pathology
associated with the metabolic syndrome (121). NAFPD is also
considered as a risk factor for pancreatic adenocarcinoma (122).
Although NAFPD and NAFLD have different natural history and
pathophysiology, both diseases are associated to obesity. In fact,
in an obesity mouse model, the combination of maternal obesity
(MO) and obesogenic diets predisposes offspring to obesity
and to NAFPD through mechanisms involving perturbations in
core circadian genes expression (123). In this model, offspring
fed obesogenic diets also developed NAFLD phenotype in
which hepatic rhythmicity of endoplasmic reticulum stress is
disrupted (124).
EPIDEMIOLOGY AND RISK FACTORS IN
PANCREATIC CANCER
The most common type of pancreatic cancer, adenocarcinoma
of the pancreas, starts with an uncontrolled growth of exocrine
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cells (forming glands and ducts) in the pancreas (125). About
95% of pancreatic cancers are adenocarcinomas, usually starting
in the pancreatic ducts. There are other types of exocrine
pancreatic cancers which are less common, as adenosquamous
carcinomas, squamous cell carcinomas or ampullary cancer, and
also endocrine pancreatic cancers, in a very low percentage (125).
Each type of pancreatic cancer can present different
characteristics and possible therapies; we will focus on the
epidemiology and risk factors of the predominant malignant
pancreatic cancer, the ductal adenocarcinoma. This is a highly
lethal malignancy, causing more than 45,000 deaths in the
United States each year, among <60 000 patients diagnosed,
which represents a very high death rate (126). According to the
latest statistics of the American Cancer Society (page)1, only 9%
of the patients will survive after 5 years since the diagnosis of
the disease. An explanation behind this is that the pancreatic
cancer presents non-specific symptoms, which lead to a delayed
diagnosis and dismal prognosis (127). Actual therapies against
pancreatic ductal adenocarcinoma include surgery, adjuvant
chemotherapy, radiation therapy (intraoperative, in which a
large dose of radiation is given to the area at the same time
as the surgery, or the proton beam radiation) and targeted
therapies (128).
The use of the different therapies against pancreatic ductal
adenocarcinoma depends on the diagnosis of the tumor
extension or staging. This is essential in order to determine tumor
respectability, which represents the only potentially curative
treatment for this cancer. The TMN (Tumor-Node-Metastasis)
classification, established by the American Joint Committee on
Cancer, is the most commonly used system for staging pancreatic
ductal adenocarcinoma into four different stages: stages I or II
(localized, resectable tumor), stage III (locally advanced tumor,
unresectable) and stage IV (metastatic tumor, unresectable).
Only 5% of tumors are classified as a borderline or potentially
resectable tumor (129).
For localized tumors (stages I and II), surgical resection
is the only potentially curative treatment. The most common
surgical technique for pancreatic tumors is cephalic duodeno-
pancreatectomy with or without pyloric preservation (127).
Some groups recommend chemo-radiotherapy as an adjuvant
treatment (130). However, other studies, including a very large
number of patients, show that only adjuvant chemotherapy
significantly improves survival and that chemo-radioterapy can
even be harmful (131). The chemotherapeutic agents used
in these cases are 5-fluoracil and gemcitabine (GEM) (127).
For the localized advanced tumors, the treatment is usually
chemotherapy with GEM or 5-fluoracil, which can be combined
with radiotherapy. However, there are no conclusive data on
a greater efficacy of chemo-radiotherapy against chemotherapy
in this type of situation (127). Finally, for metastatic aggressive
tumors, the goal of chemotherapy is mainly palliative, and it has
been shown that GEM is more advantageous than 5-fluoracil in
pain control, survival and quality of life (132). Multiple drugs
have been evaluated in combination with GEM, but none of them
1page, A.C.S.w. American Cancer Society web page [Online]. Available online at:
https://www.cancer.org/cancer/pancreatic-cancer.html [Accessed].
have shown an additive significant benefit. The only drug that
has shown a small but significant improvement when combined
with GEM is erlotinib, an inhibitor of EGFR (Epidermal Growth
Factor Receptor) (127).
Summarizing, it has been proved that the only alternative for
cure or long-term survival for patients presenting pancreatic
ductal adenocarcinoma is the surgical resection (126),
but nevertheless, the 5-years survival rate is still too low.
Identification of risk factors and early diagnosis improvements
are mandatory in order to reduce the high death rates related to
this disease (133).
The American Cancer Society divides the pancreatic cancer
risk factors in two types: the modifiable ones, such as tobacco,
overweight, diabetes, chronic pancreatitis and workplace
exposure to certain chemicals, and the non-modifiable ones:
age, gender, race, family history or chronic pancreatitis due to
a gene change (125). For example, one important risk factor,
chronic pancreatitis, has been studied in a recent meta-analysis
(134), showing that the relative risk for pancreatic ductal
adenocarcinoma in chronic pancreatitis is 13.3%, and it is even
higher in hereditary pancreatitis. This suggests that patients
with chronic pancreatitis, especially the genetic one, are a higher
risk population for this type of cancer and could be diagnosed
before (126). Other non-modifiable risk factors have been deeply
analyzed, such as age or sex: an increased incidence of pancreatic
cancer is noted with advanced age, as 60% of the patients are
older than 65 years old, and men are 30% more likely to develop
this cancer than woman, with Caucasians being less affected by
this disease than Africans Americans (135).
It is important to mention that some genetic mutations,
such as PALB2, BRCA2, or P16, have recently been identified as
potential risk factors for pancreatic ductal adenocarcinoma, due
to the increased incidence of this disease on those cases (136).
In fact, pancreatic ductal adenocarcinoma is the result of the
accumulation of successivemutations that have their origin in the
pancreatic ductal epithelium (137). This epithelium progresses
from normal to successive degrees of intraepithelial neoplasia,
becoming finally an invasive carcinoma. At the same time, there
are genetic mutations including the activation of the KRAS (90%
of cases) and inactivation of tumor suppressor genes: CDKN2A
(95% of cases), P16 (95%), P53 (50–75%), DPC4 (55%) (127).
Despite of this knowledge, the genetic basis of pancreatic cancer
is still a very complex area of study, and it presents a lot of
heterogeneity: some estimations show that this type of cancer can
present an average of 63 genetic mutations (138).
These recent results about the implication of some genetic
mutations in pancreatic ductal adenocarcinoma show the
importance of finding reliable blood markers, in order to use
them as preventive and/or prognosis biomarkers for this cancer.
The actual absence of those reduces the potential effectiveness
of a screening strategy in potential high-risk patients, even if
there are increasing researches about this topic (126). Finally,
it is important to mention that some patients with a large or
significant family history of pancreatic ductal adenocarcinoma
undergo close observation with abdominal magnetic resonance
imaging in order to anticipate the diagnosis in case of a possible
hereditary disease (139).
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Unfortunately, even if there has been a large improvement
on therapies, diagnosis procedures and study of the risk
factors, pancreatic cancer does not have an actual therapy
that significantly alters the course of pancreatic cancer, caused
mainly by the difficulties to achieve an early diagnosis for
this non-specific symptom disease (126). It is mandatory to
continue researching about prevention, risk factors, possible
prognosis or diagnosis biomarkers and combined/new therapies




Few studies have shown specifically the influence of circadian
clock genes on the biology of pancreatic cancer development
and on the efficacy of the actual therapies used for the clinical
management of the disease (140–143). Some of them report the
effect of disruption of central clock on cancer growth in animal
models. Disruption of SNC in mice induces downregulation
of p53 and overexpression of c-Myc (144) and accelerates the
growth of implanted human tumor cells from both osteosarcoma
and pancreatic adenocarcinoma (145, 146). Circadian clock genes
manipulation through controlled meal time in mice carrying
small pieces of human pancreatic adenocarcinoma results in
cancer grown inhibition by 40% vs. mice fed ad libitum (147).
At present, most research in relation to pancreatic cancer
is focused on determining which genes are involved in the
development and progression of this type of cancer, as well
as to solve therapy resistance. Interestingly, circadian clock
genes are implicated in both areas of cancer biology. A custom
pancreas gene enriched microarray, the Pittsburgh Pancreas
Gene Enriched ARray-PittPEAR, analyzed 5,763 genes, 264 of
which were differentially expressed in pancreatic cancer vs.
normal tissue (148). In this study were identified 30 human genes
related to one of seven fly circadian genes. It was observed that
one of the four human cytochrome P450-related genes, PER1
and DEC1, and downstream effectors, such as ubiquitin specific
protease 30 were significantly under-expressed in pancreatic
cancer (148, 149). A most completed retrospective study using
an integrated approach joining genomic, transcriptomic and
clinical data demonstrated that the increased expression of
ARNTL2 and NR1D1 had prognostic values for poorer survival
outcomes, indicating that these genes could be prioritized as new
therapeutic targets. Additionally, increase in tumor promoting
properties resulted from circadian dysregulation is exacerbated
by hypoxia. Therefore, the clock-hypoxia model may be used for
delineation of patients to support adjuvant therapy with hypoxia-
reducing drugs in combination with mainstream chemotherapy
and radiotherapy (150).
Prospective analysis of circadian genes expression in
patients with pancreatic ductal adenocarcinoma revealed lower
expression of PER1, PER2, PER3, CRY1, CRY2, TIPIN, TIM,
CK1E, BMAL-ARNTL, and CLOCK in cancer tissues compared
to their matched adjacent tissue. It was also found a significant
association between low expression levels of circadian genes and
reduced survival (142). Specifically, high expression of PER2
correlates with lower mortality (151). BMAL1 overexpression
significantly inhibited cell proliferation and invasion, and
induced G2/M cell cycle arrest, whereas BMAL1 knockdown
promoted pancreatic cancer growth in vitro, probably by directly
binding to the p53 gene promoter and thereby transcriptionally
activating the downstream tumor suppressor pathway in a
p53-dependent manner (152). In fact, immunohistochemistry
analysis of Bmal1 in tumor tissues from 87 patients with
pancreatic ductal adenocarcinoma showed lower levels of this
protein compared with adjacent non-tumor tissues and low
Bmal1 expression was associated with tumor progression and
poor prognosis (143). In addition, high expression of CRY2 and
low expression ofDEC1were associated with favorable prognosis
in pancreatic cancer patients (153). Further, overexpression of
mouse Period2 gene (mPer2) in human pancreatic cancer cells
reduced cellular proliferation and induced apoptotic cell death
(141). Contrary to this, other authors found higher expression of
PER1 in pancreatic tumors vs. normal tissues (154). This gene
acts as an intermediate in the inhibitory effects of TNFα (155)
and its down-regulation increased apoptosis in vitro (154).
Currently there are few published studies on polymorphisms
and pancreatic cancer (20). Cotterchio et al. found an association
between the SNP rs12913421 in RORα and pancreatic cancer,
although the significance was very weak (156).
Actually, the most effective treatment in pancreatic cancer
is surgery resection together with neoadjuvant chemotherapy,
as mentioned before. This scheme of treatment can include:
GEM mono-therapy; oxaliplatin, irinotecan, fluorouracil, and
leucovorin (FOLFIRINOX); GEM, docetaxel, capecitabine
(GTX); GEM along with cisplatin; and the nanoparticle abraxane
or albumin-bound (nab) paclitaxel along with GEM. The
objective of GEM treatment is to inhibit DNA replication and,
therefore, tumor growth but a high percentage of patients
showed resistance to this treatment (157). Nowadays, different
ways of treatment are being investigated as non-coding
RNA, nanoparticles and liposome drugs, immunotherapy;
chemoresistance related signaling pathway antagonists,
molecular therapy and specific antibiotics to bacterial
drug-activated enzyme (157, 158). Recently, it was reported
that the molecular clockwork within malignant human
pancreatic epithelium disruption and resistance to GEM is
mediated by miR-135b-induced BMAL1 repression. Moreover,
authors found that YY1 transcriptionally activated miR-135b
and formed a “miR-135b-BMAL1-YY1” loop, which has
significant predictive and prognostic value for patients with
pancreatic cancer (159). PER2 has a critical role in controlling
the malignancy of cancers and also showed a mechanism
regulating the resistance of oncogene-transformed PER2m/m
cells against the cytotoxicity of chemotherapeutic drugs. PER2
mutated cannot be translocated to the nucleus to bind to
histone deacetylase (HDAC) preventing the deacetylation of
H3K9, this causes an increase in the expression of aldehyde
dehydrogenase 3a1 (ALDH3A1) that blocks ROS generated
by chemotherapeutic agents (160). Reduction of Bcl-XL
expression levels induced by overexpression of mPER2
may influence the sensitivity to anticancer agent cisplatin
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(CDDP) in human pancreatic cancer cells enhancing tumor
death (141).
From an epigenetic point of view, drugs are developed to
reverse the global epigenetic alterations that occur in cancer.
Inhibitors of DNAmethylation can be used in single or combined
therapy to synergistically induce apoptosis of tumor cells and
reverse resistance to therapy in some types of cancer, including
pancreatic cancer. Several inhibitors of HDAC are currently
in clinical trials, showing less toxicity and adverse effects than
conventional cancer therapies (33, 161). Although the link
between the circadian epigenome and cancer remains unclear, it
has been used as a clinical approach in the treatment of cancer in
vitro and in vivomodels of the disease (33). Therefore, they could
be used as treatments for pancreatic cancer, given that numerous
studies have shown the presence of alterations in the expression
of HDACS in this type of cancer.
High HDAC4 and HDAC7 expression were significantly
associated with the presence of adenocarcinomas of the pancreas
(162, 163). Suberoylanilide hydroxamic acid (SAHA) is an
irreversible pan HDAC inhibitor, which was approved for the
treatment of cutaneous T-cell lymphoma (164). This drug
inhibits class I and II HDACs with higher IC50 for HDAC 4, 7,
and 9 (165). SAHA also appears to be a promising therapeutic
approach alone or in combination with sorafenib for the
treatment of HCC (166). MC1568 is another HDAC7 inhibitor
that improves insulin secretion from type 2 diabetes patients
and rescues β-cell dysfunction caused by HDAC7 upregulation
(167). These drugs could be assayed for the treatment of
pancreatic cancer.
SIRT1 is a very important regulator and potential therapeutic
target in pancreatic carcinogenesis and in advanced pancreatic
cancer. Its overexpression is associated with metastasis of
pancreatic ductal adenocarcinoma and promotes migration and
growth of pancreatic cancer cells (168). This could be related with
the ability of SIRT1 to reduce E-cadherin transcription activity
increasing cell EMT (169). Other sirtuins, such as SIRT3 and
SIRT7 also possess tumor suppressor properties in pancreatic
cancer. In addition, SIRT3 may represent a predictive biomarker
of response to chemotherapy (170).
SIRT1 regulates a large number of proteins often functionally
implicated in tumor development and progression (171, 172).
SIRT1 and deleted in breast cancer 1 (DBC1) co-express in
the nuclei of exocrine pancreas. In acinar-to-ductal metaplasia
(ADM), Dbc1 remains in the nucleus whereas SIRT1 underwent
a transient nuclear-to-cytoplasmic shuttling and regulates acinar
cell differentiation. Furthermore, inhibition of SIRT1 is effective
in suppression of ADM and in reducing cell viability in
established pancreatic tumors, where it acts as an independent
prognostic factor for survival in patients (173). The sensitivity
of pancreatic cancer cells to the Sirt1/2 inhibitor Tenovin-6
correlates with the levels of SIRT1/Dbc1 suggesting that Dbc1
can be a biomarker for those pancreatic tumors that could
benefit from SIRT1-inhibitory drugs (174). Capsaicin induces
apoptosis in pancreatic cancer in vitro leading to the acetylation
of FOXO-1 through activation of CBP and inhibition of SIRT-1
(175). Plumbagin (PLB), an active naphthoquinone compound,
promotes cell cycle arrest and autophagy but inhibits EMT
phenotype in pancreatic cancer cells with the involvement of
SIRT1 (176). Similarly, alisertib (ALS), a potent and selective
Aurora kinase A inhibitor, induces cell cycle arrest and autophagy
and suppresses EMT involving PI3K/Akt/mTOR and SIRT1-
mediated signaling pathways in human pancreatic cancer cells
(177). Contrary to the above results, the SIRT1-activating
compounds SRT1720, SRT1460, and SRT3025 inhibit cell growth
and survival of pancreatic cancer cells and enhance the sensitivity
of pancreatic cells to GEM and paclitaxel (178).
Combined therapy of GEMwith inhibition of SIRT1, improve
efficacy and survival time in a pancreatic cancer xenogeneic
mice model, compared with single inhibition of SIRT1, or single
GEM therapy (179), probably due to the implication of SIRT1 in
chemo-sensitivity of pancreatic cancer cells (180). SIRT1 seems
to be involved in the adaptive response of pancreatic cancer
cells to chemotherapy-induced DNA damage stress (181). The
SIRT1 inhibitor 6-chloro-2,3,4,9-tetrahydro-1 H-Carbazole-1-
carboxamide (EX527) enhanced sensitivity of pancreatic cancer
cells to GEM treatment through increased apoptosis (182). In
line with this, two MDM2 inhibitors (MI-319 and MI-219)
synergistically augmented anti-tumor effects of therapeutic drug
GEM in pancreatic cancer in vitro and in vivo experimental
models trough the reactivation of p53 pathway and targeting
SIRT1 and Ku70 (183). In addition, resistance to TRAIL-induced
apoptosis seems to be mediated by SIRT1 and HDAC3 (184).
There is intense research to identify nontoxic but high
potency inhibitors of SIRT1 (185). Melatonin or (N -acetyl-
5-methoxytryptamine) is a phylogenetically well-preserved
indoleamine synthesized from tryptophan in the pineal gland and
in other many tissues of human body (186). Anti-tumor effects
of this indoleamine have been described in vitro and in vivo
models of this disease as single or combined therapy (187–189).
In the case of combined therapy, it has been shown to increase
the efficacy and decrease the toxicity of the current treatments of
cancer (190). Many mechanisms have been proposed to explain
the effects of melatonin in cancer. As an important regulator of
circadian rhythms, it acts on different types of cancer, including
pancreatic cancer (189, 191). Direct and indirect approaches
showed a dual relationship between melatonin and SIRT1 in
normal and tumor cells. In several cancer models, melatonin
inhibits SIRT1 activity. However, there are no direct evidences
showing a role for melatonin in regulating cancer cell growth
through SIRT1/circadian clock axis (192). Melatonin can also
be found in mitochondria of mammalian cells were it seems
to activate SIRT3 leading to decreased ROS production, among
other effects. Given the relationship between redox homeostasis
of the cells and the circadian clock, this could be an indirect
mechanism by which melatonin could regulate the circadian
clock in cancer cells through sirtuins, although it has not been
yet studied (193).
Given the importance of SIRT1 in pancreatic cancer
regulation, it was expected that NAD synthesis and degradation
had an important role in tumor cell metabolism and growth
as well (194). Pharmacologic and genetic targeting of NAMPT,
the key enzyme in the NAD salvage synthesis pathway,
inhibits cell growth and survival of pancreatic cancer cells.
The responsiveness to NAMPT inhibition is modulated by
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FIGURE 1 | Schematic representation of factors driving alterations in the molecular clock that lead to the development of pancreatic cancer and resistance to
chemotherapy.
the expression of CD38. However, neither SIRT1 nor PARP-1
(another NAD+ dependent enzyme) play a significant role on the
effect of NAMPT inhibition on pancreatic cancer cells (194).
Other pharmacological approaches can be directed to some
miRNAs responsible for the regulation of SIRT1 expression.MiR-
34a is known to be downregulated in the majority of pancreatic
cancers. It is a component of the p53 transcriptional network and
regulates cancer stem cell survival. Its restitution using a systemic
nanovector inhibits pancreatic cancer growth in mice and
decreases SIRT1 expression (195). Interestingly, demethylating
agent 5-Aza-2’-deoxycytidine (5-Aza-dC) and HDAC inhibitor
SAHA can also restore miR-34a expression in human pancreatic
cancer stem cells (CSCs) and in human pancreatic cancer
cell lines and strongly inhibit the cell proliferation, cell cycle
progression, self-renewal, epithelial to mesenchymal transition
(EMT) and invasion (196). Ectopic expression of miR-217
inhibited TGF-β1-induced EMT by downregulating SIRT1 in
chronic pancreatitis and pancreatic cancer (197), while miR-
494 inhibited the proliferation, invasion and chemoresistance of
pancreatic cancer by regulating SIRT1 and c-Myc (198). MiR-
601 also inhibits SIRT1 and its expression is significantly lower
in cancer samples, especially in metastatic compared to non-
metastatic pancreatic cancer tissues (199).
Autophagy is the dynamic process by which unnecessary or
dysfunctional cytosolic proteins and organelles are degraded
in order to maintain cell homeostasis. It is activated under
extracellular (starvation, hypoxia and infection) and intracellular
(accumulation of damaged molecules and high bioenergetics
demand) stress conditions (200). Nutrient limitation or
starvation is a frequent feature of the cellular microenvironment
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in the core of solid tumors. The predominant role of autophagy in
cancer cells is to confer stress tolerance, which serves to maintain
tumor cell survival (201) by altering metabolic conditions (200).
Autophagy has been associated to pancreatic cancer and
activated autophagy supports tumor growth and plays a role
in the lack of effect of current treatments (202). The effects
of autophagy modulation in this cancer seem to depend on
both tumor specific properties and the chemotherapy schedule
(203). However, the mediators that regulate the crosstalk
between autophagy and apoptotic death in cells exposed to
extreme nutrient starvation in pancreatic cancer are not fully
understood. Recent studies suggested that glucose starvation
induces progressive autophagy trough GPx1 degradation and
inhibition of glycolysis activation and subsequent activation
of ROS/AMPK signaling (204). Other studies showed the
implication of mTORC1 in the induction of autophagy by
starvation in several types of cancer, including pancreatic
cancer. MiT/TFE transcription factors, master regulators of
lysosomal and melanosomal biogenesis and autophagy, control
mTORC1 lysosomal recruitment and activity by directly
regulating the expression of RagD (205). Wong and coworkers
demonstrated the induction of autophagy by serum plus
amino acids starvation in pancreatic ductal adenocarcinoma
cells. Suppression of mTORC1 activity by starvation but not
mTORC1 inhibitors triggers dissociation of PP2A from its
inhibitor Alpha4 and ULK1 dephosphorylation at S637 (206).
On these conditions, a signaling cascade involving AMPK and
SIRT1 displaces chromatin-bound BRD4, inducing autophagy
gene activation and cell survival (207). On the other hand,
miR-138-5p suppresses autophagy by directly targeting SIRT1
expression and inhibits mTOR dephosphorylation under serum
starvation-induced autophagy in pancreatic cancer (208). These
mechanisms could be under the control of circadian clock
trough SIRT1. In fact, serum starvation of pancreatic cancer
in vitro induces increased SIRT1 activity and decreased levels
and temporal patterns of expression of circadian clock genes in
vitro (151).
Taking together, all this results showed the feasibility of
the direct or indirect handling of circadian clock as an
approach to treat pancreatic cancer. Optimizing the time of
drug administration may also offer an improvement of drug
efficacy and safety without neither increasing drug doses nor
changing drug types. Currently, several randomized controlled
trials and clinical practices highlight the validity of circadian-
based treatments (209). However, the absence of a systematic
computation for circadian timing in cancer therapies makes it
a challenge (210). In addition, a comprehensive characterization
of clock genes and their clinical relevance in cancer is also
necessary. In line with this, Ye and coworkers analyzed genomic
profiling and clinical data from 32 cancer types, including
pancreatic cancer, from The Cancer Genome Atlas (TCGA)
(211), the Cancer Therapeutics Response Portal (CTRP) (212),
and Genomics of Drug Sensitivity in Cancer (GDSC) databases
(213). They found alterations of clock genes at transcriptional,
genetic and epigenetic levels and identified ARNTL2, NR1D1,
and NPAS2 as probable oncogenes and PERs, CRYs, RORs
as gene suppressors of tumors. Transcriptional dysregulation
of clock genes is strongly associated with patient survival,
tumor stage, and subtype. Further, they identified the effect
of dysregulated clock genes on different signaling pathways
and the potential therapeutic effects of clock genes in cancer
chronotherapy. Their results highlight the potential therapeutic
use of the right time schedule of a treatment in cancer as
well as the need to personalize chronotherapy. However, more
research is necessary in this field because the results concerning
drugs effect were obtained from cells and the time at which the
specimen from patients were obtained is unknown (59).
CONCLUDING REMARKS
Pancreatic cancer is one of the most deadly types of cancer
due to the lack of early diagnosis and to the lack of
specific molecular targets for its treatment, despite the
efforts made in recent decades in this regard. The use of
personalized medicine is crucial, as clinical heterogeneity
is a hallmark of this disease. Molecular clock disruption
through several ways leads to carcinogenesis, tumor growth
and therapy resistance (Figure 1). In this sense, components
of molecular circadian clock are emerging tools that can
be used as prognostic factors for effectivity of commonly
used chemotherapies and for the development of new
treatments. Despite the results obtained in this field of
research, the clinical trials necessary to take advantage of
them have not been launched. On the contrary, in relation to
prognosis, controversial results obtained from patients make
necessary more research before to use circadian molecular
clock components as biological markers of disease prognosis
and outcome.
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